Preclinical studies indicate that combining CQ or HCQ with BRAF inhibitors, MEK inhibitors, or immunotherapy can enhance the cytotoxic effects of these drugs on melanoma cells [205,206,207,208,209] (NCT01844505). Here, MAP2K7 is linked to melanoma.